TY - JOUR
KW - buprenorphine
KW - buprenorphine/naloxone
KW - Injectable naltrexone
KW - opioid use disorder
KW - oral naltrexone
KW - Treatment discontinuation
AU - Jake R. Morgan
AU - Bruce R. Schackman
AU - Jared A. Leff
AU - Benjamin P. Linas
AU - Alexander Y. Walley
A1 - 
AD - Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, MA, USA. Electronic address: jakem@bu.edu.; Department of Healthcare Policy & Research, Weill Cornell Medical College, New York, NY, USA.; Department of Healthcare Policy & Research, Weill Cornell Medical College, New York, NY, USA.; Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.; Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Boston, MA, USA.
BT - Journal of substance abuse treatment
C5 - Financing & Sustainability; Opioids & Substance Use
CY - United States
DO - 10.1016/j.jsat.2017.07.001
JF - Journal of substance abuse treatment
LA - eng
M1 - Journal Article
PB - Elsevier Inc
PP - United States
PY - 2018
SN - 1873-6483; 0740-5472
SP - 90
EP - 96
EP - 
T1 - Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population
T2 - Journal of substance abuse treatment
TI - Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population
U1 - Financing & Sustainability; Opioids & Substance Use
U2 - 28733097
U3 - 10.1016/j.jsat.2017.07.001
VL - 85
VO - 1873-6483; 0740-5472
Y1 - 2018
Y2 - Feb
ER -